2025 Financial Outlook
For full-year 2025: Baxter expects sales growth from continuing operations of 5% to 6% on a reported basis. On an operational basis,4 Baxter expects sales growth of 4% to 5%. The company expects adjusted earnings from continuing operations, before special items, of $2.45 to $2.55 per diluted share.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.